CU23795A3 - Formulaciones líquidas de anticuerpo antirrábico - Google Patents

Formulaciones líquidas de anticuerpo antirrábico

Info

Publication number
CU23795A3
CU23795A3 CU20090099A CU20090099A CU23795A3 CU 23795 A3 CU23795 A3 CU 23795A3 CU 20090099 A CU20090099 A CU 20090099A CU 20090099 A CU20090099 A CU 20090099A CU 23795 A3 CU23795 A3 CU 23795A3
Authority
CU
Cuba
Prior art keywords
antibody
antirrabic
liquid formulations
formulations
rabies
Prior art date
Application number
CU20090099A
Other languages
English (en)
Inventor
Willem Egbert Marissen
Alexander Berthold Hendrik Bakker
Original Assignee
Crucell Holland Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Crucell Holland Bv filed Critical Crucell Holland Bv
Publication of CU23795A3 publication Critical patent/CU23795A3/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Virology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Mycology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Dermatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

La presente invención se refiere a formulaciones farmacéuticas de anticuerpo, en particular formulaciones líquidas farmacéuticas que comprenden anticuerpos de virus de la rabia. Las formulaciones se pueden usar en la profilaxis post-exposición de la rabia
CU20090099A 2006-12-05 2009-06-04 Formulaciones líquidas de anticuerpo antirrábico CU23795A3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US87289206P 2006-12-05 2006-12-05
EP06125400 2006-12-05

Publications (1)

Publication Number Publication Date
CU23795A3 true CU23795A3 (es) 2012-03-15

Family

ID=39092188

Family Applications (1)

Application Number Title Priority Date Filing Date
CU20090099A CU23795A3 (es) 2006-12-05 2009-06-04 Formulaciones líquidas de anticuerpo antirrábico

Country Status (13)

Country Link
US (1) US7959922B2 (es)
EP (1) EP2088997B1 (es)
JP (1) JP5410985B2 (es)
KR (1) KR101522036B1 (es)
CN (1) CN101557799B (es)
AU (1) AU2007328960B2 (es)
CA (1) CA2668947C (es)
CU (1) CU23795A3 (es)
EA (1) EA017549B1 (es)
IL (1) IL199004A (es)
MX (1) MX2009005414A (es)
WO (1) WO2008068246A1 (es)
ZA (1) ZA200902772B (es)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2322547A1 (en) 2003-06-25 2011-05-18 Crucell Holland B.V. Myeloid cell-specific lectin
CN102212132A (zh) 2004-05-27 2011-10-12 克鲁塞尔荷兰公司 能中和狂犬病病毒的结合分子及其应用
US8211431B2 (en) 2006-06-06 2012-07-03 Crucell Holland B.V. Human binding molecules having killing activity against staphylococci and uses thereof
WO2008068246A1 (en) 2006-12-05 2008-06-12 Crucell Holland B.V. Liquid anti-rabies antibody formulations
JP2010085126A (ja) * 2008-09-29 2010-04-15 Adtec Kk 狂犬病ウイルス中和抗体価判定具および狂犬病ウイルス中和抗体価の測定方法
US8821879B2 (en) 2009-09-04 2014-09-02 Xoma Technology Ltd. Anti-botulism antibody coformulations
KR102196009B1 (ko) 2011-10-25 2021-01-04 프로테나 바이오사이언시즈 리미티드 항체 제형 및 방법
HUE031290T2 (hu) * 2012-03-07 2017-06-28 Lilly Co Eli IL-17 antitest készítmény
KR20140119396A (ko) 2013-03-29 2014-10-10 삼성전자주식회사 단백질 약물의 액상 제형
WO2018204374A1 (en) 2017-05-02 2018-11-08 Merck Sharp & Dohme Corp. Formulations of anti-lag3 antibodies and co-formulations of anti-lag3 antibodies and anti-pd-1 antibodies
JOP20190260A1 (ar) 2017-05-02 2019-10-31 Merck Sharp & Dohme صيغ ثابتة لأجسام مضادة لمستقبل الموت المبرمج 1 (pd-1) وطرق استخدامها
JP7159642B2 (ja) * 2018-06-26 2022-10-25 東ソー株式会社 カラムの抗体に対する保持力の測定方法
JP2023529010A (ja) 2020-06-12 2023-07-06 ナンチン リーズ バイオラブス カンパニー，リミティド Ｔｎｆｒ２に結合する抗体およびその用途
CN114748618B (zh) * 2022-04-02 2024-07-19 重庆智翔金泰生物制药股份有限公司 包含针对狂犬病病毒g蛋白的双特异性抗体的药物制剂及其制备方法

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0402029B1 (en) 1989-06-08 1994-01-12 The Wistar Institute Monoclonal antibodies for post exposure treatment of rabies
DE4006630A1 (de) 1990-03-03 1991-09-12 Behringwerke Ag Humane monoklonale antikoerper gegen tollwutviren, ihre herstellung und verwendung
JP2001512560A (ja) 1996-10-08 2001-08-21 ユー―ビスイス ベスローテン フェンノートシャップ 標的に対し特異的な親和性を有するペプチドおよびタンパク質の選択のための方法および手段
US20040013672A1 (en) 2000-05-16 2004-01-22 Thomas Jefferson University Recombinant antibodies, and compositions and methods for making and using the same
AU2002332600B2 (en) 2001-08-21 2007-03-22 Thomas Jefferson University Recombinant antibodies, and compositions and methods for making and using the same
SI1523496T1 (sl) 2002-07-18 2011-11-30 Merus B V Rekombinantno proizvajanje zmesi protiteles
CA2537371A1 (en) 2003-09-04 2005-03-17 Crucell Holland B.V. Antigenic peptides of rabies virus and uses thereof
WO2005035573A1 (ja) * 2003-10-09 2005-04-21 Chugai Seiyaku Kabushiki Kaisha タンパク質溶液の安定化方法
EP1688432B1 (en) * 2003-10-09 2011-08-03 Chugai Seiyaku Kabushiki Kaisha Igm high concentration stabilized solution
JPWO2005063291A1 (ja) * 2003-12-25 2007-07-19 麒麟麦酒株式会社 抗体を含有する安定な水性医薬製剤
CN102212132A (zh) * 2004-05-27 2011-10-12 克鲁塞尔荷兰公司 能中和狂犬病病毒的结合分子及其应用
KR101280273B1 (ko) * 2005-04-18 2013-07-15 예다 리서치 앤드 디벨럽먼트 캄파니 리미티드 안정화된 항-ｂ형 간염 바이러스 (ｈｂｖ) 항체 제형
WO2008068246A1 (en) 2006-12-05 2008-06-12 Crucell Holland B.V. Liquid anti-rabies antibody formulations

Also Published As

Publication number Publication date
CA2668947A1 (en) 2008-06-12
JP2010511665A (ja) 2010-04-15
IL199004A (en) 2015-10-29
KR101522036B1 (ko) 2015-05-20
EP2088997B1 (en) 2016-08-24
US20100034829A1 (en) 2010-02-11
AU2007328960A1 (en) 2008-06-12
CN101557799B (zh) 2012-08-22
ZA200902772B (en) 2012-09-26
AU2007328960B2 (en) 2013-01-17
WO2008068246A1 (en) 2008-06-12
EA200970533A1 (ru) 2009-10-30
CA2668947C (en) 2017-02-07
JP5410985B2 (ja) 2014-02-05
EA017549B1 (ru) 2013-01-30
MX2009005414A (es) 2009-06-01
US7959922B2 (en) 2011-06-14
IL199004A0 (en) 2010-02-17
CN101557799A (zh) 2009-10-14
KR20090089881A (ko) 2009-08-24
EP2088997A1 (en) 2009-08-19

Similar Documents

Publication Publication Date Title
CU23795A3 (es) Formulaciones líquidas de anticuerpo antirrábico
AR116860A2 (es) Composición que comprende anticuerpo que se fija al dominio ii de her2, y sus variantes ácidas
CY1120413T1 (el) Ειδικα εξανθρωπισμενα αντισωματα στην πρωτοϊνιδιακη μορφη του βητα-αμυλοειδους πεπτιδιου
CY1116261T1 (el) Αντισωματα και ανοσοσυζευγματα και χρησεις αυτων
CY2016030I2 (el) Αντισωματα εναντι της il-17
CY1115091T1 (el) Διειδικες πρωτεϊνες προσδεσης αντιγονων
CL2008003910A1 (es) Formulacion liquida, estable, conteniendo anticuerpo que comprende arginina y metionina; procedimiento para inhibir la deamidacion de moleculas de un anticuerpo que comprende agregar arginina a la formulacion liquida.
CR20160206A (es) Composiciones y métodos para anticuerpos que se dirigen a la proteína de complemento C5
AR060130A1 (es) Formulacion de un anticuerpo monoclonal humano anti- igf-1r
HN2009000379A (es) Anticuerpo especifico prlr y sus usos
ECSP10010295A (es) Formulacion de anticuerpo
AR088920A1 (es) Purificacion de anticuerpos anti-c-met
CY1114926T1 (el) Αντισωματα και ανοσοσυζευγματα και χρησεις αυτων
BR112014012275A2 (pt) purificação de proteína com a utilização de tampão bis-tris
CR11548A (es) Azolilmetiloxiranos, su uso y agentes que los contienen
CL2010001426A1 (es) Compuestos derivados de triciclos, inhibidores de la proteina quinasa; composicion farmaceutica que los comprende; utiles en el tratamiento de enfermedades oncologicas e inmunologicas.
CO5720212A1 (es) Composicion de anticuerpo her2
BR112012015721A2 (pt) modificação covalente de proteínas dirigida por ligante
MA32712B1 (fr) Anticorps anti-vegf/anti-ang-2 bispecifique
BRPI0810851A2 (pt) Compostos de enxofre com inibidores da serina protease ns3 do vírus da hepatite c
MX344040B (es) Anticuerpos mejorados de la clase inmonoglubina g4 (igg4).
UY31562A1 (es) Azolilmetiloxiranos, su uso y agentes que los contienen
CR10555A (es) Vacunas para malaria
EA200970247A1 (ru) Способ получения оптического активного n-защищенного 3-аминопирролидина или оптически активного n-защищенного 3-аминопиперидина и соответствующих кетонов путем оптического разделения рацемических смесей аминов с использованием бактериальной омега-трансаминазы
CL2011001769A1 (es) Composición para estimular una respuesta inmune contra la toxina shiga stx2 que comprende polipéptidos que comprenden al menos dos de las tres regiones que definen un epitopo conformacional exclusivo de stx2, los cuales se insertan dentro de una proteína andamio no stx2; dicho polipéptido; ácido nucleico; y método de producción de anticuerpos.

Legal Events

Date Code Title Description
FG Grant of patent
FD Lapse (for not paying fees)